Biomea Fusion, Inc. · NASDAQ:BMEA
Biomea Fusion — 2026 J.P. Morgan Healthcare Conference
27 slides from Biomea Fusion's conference presentation, Jan 14, 2026
Slide 1: 2026 J.P. Morgan Healthcare Conference
2026 J.P. Morgan Healthcare Conference Mick Hitchcock, CEO Biomea Fusion January 14, 2026 Exhibit 99.1
Slide 2: Legal Disclaimer & Forward-looking Statements
Legal Disclaimer & Forward-looking Statements Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future business and financial performance of Biomea Fusion, Inc. (the “Company”) and involve know
Slide 3: Biomea Fusion – Development Candidates
Biomea Fusion – Development Candidates Icovamenib Diabetes Oral Small molecule COVALENT-111 (Phase 2) Insulin-deficient Type 2 Diabetes (T2D) GLP-1 inadequately controlled BMF-650 (GLP-1 RA) Weight loss Oral Small molecule GLP-131 (Phase 1) Obese (BMI ≥30kg/m2)
Slide 4: Existing T2D Treatments Address Symptoms, Not Disease Progression
Existing T2D Treatments Address Symptoms, Not Disease Progression Existing T2D therapies primarily address downstream metabolic symptoms Icovamenib is a selective and partial menin inhibitor, targeting a previously unaddressed pathway Zhou, Nat Rev Endocrinol, 2016 Metformin Glucose uptake TZDs Gluc
Slide 5: The Root Cause of Diabetes: Progressive beta-cell failure
The Root Cause of Diabetes: T2D is driven by progressive beta-cell failure UNDIAGNOSED Time of diabetes diagnosis Beta-cell function is ~50% of normal at time of T2D diagnosis Adapted from Lebovitz, Diabetes Rev, 1999
Slide 6: T2D Remains a Growing Health Burden in the US
T2D Remains a Growing Health Burden in the US 1CDC, Natl. Diabetes Stat. Rep., 2022; 2ADA, Standards of Care in Diabetes, Diabetes Care, 2024; 3Ahlqvist, Lancet Diabetes Endocrinol., 2018
Slide 7: Severe Insulin-Deficient Diabetes Patients: HbA1c Results
Severe Insulin-Deficient Diabetes Patients | 12 Weeks of icovamenib Dosing (9 Months After Last Dose) Arm A was excluded from this analysis because it included only 8 weeks of dosing which the company is not planning to pursue Icovamenib Treatment Period 0.3 -1.2 P=0.01
Slide 8: Icovamenib Increased Insulin Secretion as Measured by C-peptide Index
Icovamenib Increased Insulin Secretion as Measured by C-peptide Index All severe insulin-deficient patients (All Arms) 29% 2% Data censored at onset of rescue medication, defined as any modification in antihyperglycemic therapy Icovamenib Treatment Period
Slide 9: Why did HbA1c decrease beyond weeks?
Why did HbA1c decrease beyond 12 weeks? Menin suppressed beta-cell proliferation and function Demonstrated to act as a biological brake on insulin-producing cells in T2D Menin inhibition was shown to lift this brake Enabled control on beta-cell regeneration and restoration of insulin secretory capac
Slide 10: Physiologic Suppression of Menin Can Expand Beta-Cell Mass
10 Physiologic Suppression of Menin Can Expand Beta-Cell Mass Physiologic states such as pregnancy and lactation suppress menin, enabling beta-cell expansion and increased insulin output Preclinical and human data consistently link reduced menin signaling to improved beta-cell mass and function Icov
Slide 11: Inhibiting Menin in Rats and Human Islet Cells Demonstrates Proliferative Effect
A. Vehicle; Day 31 B. Pioglitazone; Day 17 C. icovamenib; Day 31 ZDF Diabetic Model: A) Vehicle-treated animal, Day 31. Beta islets display low congregation and growth, while alpha cells dominate. B) Pioglitzaone-treated animal, Day 17. Beta islets display congregation and growth. C) Icovamenib trea
Slide 12: Post-hoc Analysis of Patients on a GLP-1 Based Therapy Not Achieving Target HbA1c
Post-hoc Analysis of Patients on a GLP-1 Based Therapy Not Achieving Target HbA1c <7% at Enrollment (9 Months After Last Dose) Icovamenib Treatment Period 0.55 -1.19 P=0.05
Slide 13: Icovamenib Enhanced GLP-1 Receptor and Insulin Transcript Levels
Icovamenib Enhanced GLP-1 Receptor and Insulin Transcript Levels Culture 7 days under hyperglycemic conditions (8 mM glucose) Cadaver derived human islets Gene expression Mean Fold Change -∆∆ct±SD Mean Fold Change -∆∆ct±SD
Slide 14: Overview of Treatment Emergent Adverse Events Through 52 Weeks
Overview of Treatment Emergent Adverse Events (TEAEs) Through 52 Weeks Parameter Placebo Combined arms (N=66) Icovamenib Combined arms (N=201) Arm A icovamenib (N=67) Arm B icovamenib (N=67) Arm C icovamenib (N=67) Patients with ≥1 TEAE, N (%) 18 (27) 55 (27) 19 (28) 22 (33) 14 (21) Treatment-Relate
Slide 15: Treatment Emergent Adverse Events Occurring in ≥5% in Any Study Arm
Treatment Emergent Adverse Events (TEAEs) Occurring in ≥5% in Any Study Arm and TEAEs Reported for ALT and/or AST Elevations Parameter Placebo Combined arms (N=66) icovamenib Combined arms (N=201) Arm A icovamenib (N=67) Arm B icovamenib (N=67) Arm C icovamenib (N=67) Diarrhea, N (%) 0 7 (3) 4 (6) 2
Slide 16: Icovamenib in T2D: 52-Week Highlights
Icovamenib in T2D: 52-Week Highlights Durable treatment effect in severe insulin-deficient T2D Continued benefit observed in severe insulin-deficient diabetes patients Higher icovamenib exposure (PK) led to improved responses PK analysis shows that greater HbA1c reductions occurred in patients with
Slide 17: COVALENT-111: Potential to Alter the Insulin Treatment Trajectory
COVALENT-111: Potential to Alter the Insulin Treatment Trajectory COVALENT-111 highlights the potential to restore endogenous insulin production capacity in patients who would otherwise progress to chronic insulin therapy—offering the possibility of short-term oral treatment rather than lifelong inj
Slide 18: COVALENT-211: A Phase II Trial of Icovamenib in T2D
COVALENT-211: A Phase II Trial of Icovamenib in Participants with T2D Who Are Not Achieving Glycemic Targets Placebo 100 mg QD Icovamenib 100 mg QD ARM A (n=40) ARM B (n=20) Stable Background Therapy SCREENING: 28 DAYS TREATMENT: 12 WEEKS FOLLOW-UP: 52 WEEKS Week 26: Primary endpoint Week 52: Second
Slide 19: COVALENT-212: A Phase II Trial in T2D on GLP-1-Based Therapy
Placebo 100 mg QD Icovamenib 100 mg QD ARM A (n=40) ARM B (n=20) Background Therapy: Stable GLP-1-based therapy SCREENING: 28 DAYS TREATMENT: 12 WEEKS FOLLOW-UP: 52 WEEKS Week 26: Primary endpoint Week 52: Secondary endpoint FOLLOW-UP: 26 WEEKS Key Inclusion Criteria Adult participants with T2D who
Slide 20: Mechanism of Action of Icovamenib – a Selective and Partial Menin Inhibitor
Increased beta cell mass and function Increased insulin synthesis and secretion DUAL EFFECT BETA CELL QUANTITY & FUNCTION GLP-1 RECEPTOR EXPRESSION Increased GLP-1 receptor expression and GLP-1 release; enhanced incretin effect Enhanced weight loss with preservation of lean muscle mass in preclinica
Slide 21: Biomea Fusion – BMF-650
Biomea Fusion – BMF-650 BMF-650 (GLP-1 RA) Weight loss Oral Small molecule GLP-131 (Phase 1) Obese (BMI ≥30kg/m2) Designed for better bioavailability >>> More consistent efficacy
Slide 22: Oral BMF-650 Promoted Body Weight Reduction in Obese Cynomolgus Monkeys
Oral BMF-650 Promoted Body Weight Reduction in Obese Cynomolgus Monkeys (5 animals per dose group) Vehicle -3.4% BMF-650 10mg/kg -12.3% BMF-650 30mg/kg -15.2% 0 -10 -20 Change from baseline (%) 7 14 21 28 Mean reduction in Body Weight (Day 29)
Slide 23: BMF-650 Has Demonstrated Favorable Liver Safety to Date
BMF-650 Has Demonstrated Favorable Liver Safety to Date Pfizer chemotype / danuglipron Danuglipron and lotiglipron discontinued3,4 TERN-601 discontinued5 Observation of LFTs elevations Chugai chemotype / orforglipron: 3000+ patients dosed in ATTAIN 1 / 2 studies1,2 No LFT signals for orforglipron BM
Slide 24: GLP-131: First-in-Human Study of an Oral Non-peptide GLP-1 Receptor Agonist
GLP-131: A Randomized, Double-blind, Placebo-controlled, FIH Study of an Oral Non-peptide GLP-1 Receptor Agonist Part 1: single ascending dose (SAD) study | Part 2 is a multiple ascending dose (MAD) study Jan ‘26
Slide 25: Overview of Key Program Activities
Overview of Key Program Activities COVALENT 211 (Phase IIB) Insulin-deficient T2D (20% of US T2D population) First patient enrollment planned in 1Q 2026 26-Week readout expected in 4Q 2026 COVALENT 212 (Phase II) T2D patients not controlled on GLP-1 based medicines (70% of US GLP-1 population) First
Slide 26: Q&A
Q&A QObiomea
Slide 27: Thank You
THANK YOU For questions or inquiries, please reach out to Meichiel Weiss at ir@biomeafusion.com www.biomeafusion.com
Biomea Fusion — 2026 J.P. Morgan Healthcare Conference on 6ix